药物和毒素诱导的克隆症 - - 一个系统化的综述,包括在多系统性缩中对阿曼塔丁诱导的克隆症的病例报告
Hugo Cannilla1, Maria Messe2, François Girardin3
1University of Lausanne, Lausanne, Switzerland.
概括
一种罕见的眼动障碍,可由毒素或影响神经传递的药物触发. 本综述强调了各种原因和药物诱导的克隆机制的复杂性.
科学领域:
- 神经科学是一个神经科学.
- 眼科医生 眼科 眼科
- 毒理学 毒理学 毒理学
背景情况:
- 奥普索克隆斯是一种罕见的神经系统疾病,其特点是不自发的眼动.
- 虽然通常是异常性或与自身免疫/神经瘤性疾病相关,但opsoclonus可以是药物诱导的.
- 在多系统性缩症中,阿曼塔丁诱导的克隆病例促使我们进行了此次审查.
研究的目的:
- 审查和分析有毒/药物诱导的opsoclonus病例.
- 为了识别常见的致病原体和受影响的神经递质系统.
- 了解药物诱导的克隆症的病理生理学.
主要方法:
- 关于有毒性/药物诱导的opsoclonus的系统文献综述.
- 基于预先定义的标准和质量评估的文章的包含.
- 对阿曼塔丁诱导的克隆单一病例报告的分析.
主要成果:
- 该审查分析了30篇文章中的158个案例.
- 最常见的原因是树皮子中毒 (74%) 和chlordecone中毒 (9%).
- 涉及到各种神经递质 (乙胆,谷氨酸,GABA,多巴胺,甘氨酸) 和通道.
结论:
- 毒性/药物诱导的克隆症是一种罕见但公认的临床实体.
- 多样化的致病剂和受影响的神经递质系统使理解潜在的病理生理学变得复杂.
- 需要进一步的研究,以阐明药物诱导的opsoclonus的复杂机制.
相关概念视频
Parkinson's Disease: Treatment
263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Parkinson's Disease: Overview
533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
Anticholinesterase Agents: Poisoning and Treatment
850
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
850
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
661
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
661
Antiepileptic Drugs: Glutamate Antagonists
321
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
321
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K


